Table of contents
Librela is a veterinary medicine used for the alleviation of pain associated with osteoarthritis in dogs. It contains the active substance bedinvetmab.
Librela : EPAR - Medicine overview (PDF/132.74 KB)
First published: 06/05/2021
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
|Date of issue of marketing authorisation valid throughout the European Union||
18/02/2022 Librela - EMEA/V/C/005180 - IB-0003
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
For the alleviation of pain associated with osteoarthritis in dogs
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 13-15 July 202116/07/2021
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 8-9 September 202011/09/2020